Non-invasive CT based multiregional radiomics for predicting pathologic complete response to preoperative neoadjuvant...

This study aims to develop and validate a multiregional radiomics model to predict pathological complete response (pCR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC), and further evaluate the performance of the model in different specific subgroups (N2 stage and anti-PD-1/PD-L1).

216 patients with NSCLC who underwent neoadjuvant chemoimmunotherapy followed by surgical intervention were included and assigned to training and validation sets randomly. From pre-treatment baseline CT, one intratumoral (T) and two peritumoral regions (P₃: 0-3 mm; P₆: 0-6 mm) were extracted. Five radiomics models were developed using machine learning algorithms to predict pCR, utilizing selected features from intratumoral (T), peritumoral (P₃, P₆), and combined intra- and peritumoral regions (T + P₃, T + P₆). Additionally, the predictive efficacy of the optimal model was specifically assessed for patients in the N2 stage and anti-PD-1/PD-L1 subgroups.

A total of 51.4 % (111/216) of patients exhibited pCR following neoadjuvant chemoimmunotherapy. Multivariable analysis identified that only the T + P₃ radiomics signature served as independent predictor of pCR (P < 0.001). The multiregional radiomics model (T + P₃) exhibited superior predictive performance for pCR, achieving an area under the curve (AUC) of 0.75 in the validation cohort. Furthermore, this multiregional model maintained robust predictive accuracy in both N2 stage and anti-PD-1/PD-L1 subgroups, with an AUC of 0.829 and 0.833, respectively.

The proposed multiregional radiomics model showed potential in predicting pCR in NSCLC after neoadjuvant chemoimmunotherapy, and demonstrated good predictive performance in different specific subgroups. This capability may assist clinicians in identifying suitable candidates for neoadjuvant chemoimmunotherapy and promote the advancement in precision therapy.